EPTINEZUMAB FOR PREVENTION OF CHRONIC MIGRAINE (CM): RESULTS OF 2 INFUSIONS IN THE PHASE 3 PROMISE-2 (PREVENTION OF MIGRAINE VIA INTRAVENOUS EPTINEZUMAB SAFETY AND EFFICACY-2) TRIAL

被引：0
|
作者：
Ashina, M. [1 ]
Goadsby, P. J. [2 ]
Lipton, R. B. [3 ]
Azimova, J. [4 ]
Winner, P. [5 ]
Schaeffler, B. [6 ]
Biondi, D. [6 ]
Bhattacharya, S. [6 ]
Smith, J. [7 ]
Cady, R. [6 ]
机构：
[1] Univ Copenhagen, Rigshosp Glostrup, Danish Headache Ctr, Copenhagen, Denmark
[2] Kings Coll London, NIHR Wellcome Trust Kings Clin Res Facil, London, England
[3] Albert Einstein Coll Med, Montefiore Headache Ctr, Bronx, NY 10467 USA
[4] Univ Headache Clin, Moscow, Russia
[5] Palm Beach Headache Ctr, Premiere Res Inst, W Palm Beach, FL USA
[6] Alder BioPharmaceut Inc, Bothell, WA USA
[7] Alder BioPharmaceut Inc, Dublin, Ireland
来源：
CEPHALALGIA | 2018年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
MTIS2018-0
引用
收藏
页码：84 / 85
页数：2
相关论文
共 50 条
  • [11] A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab in Frequent Episodic Migraine Prevention: Primary Results of the PROMISE 1 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy 1) Trial
    Saper, Joel
    Lipton, Richard
    Kudrow, David
    Hirman, Joe
    Dodick, David
    Silberstein, Stephen
    Chakhava, George
    Smith, Jeff
    Biondi, David
    CEPHALALGIA, 2017, 37 : 337 - 337
  • [12] Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial
    Dodick, David W.
    Lipton, Richard B.
    Silberstein, Stephen
    Goadsby, Peter J.
    Biondi, David
    Hirman, Joe
    Cady, Roger
    Smith, Jeff
    CEPHALALGIA, 2019, 39 (09) : 1075 - 1085
  • [13] Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2
    Apelian, Rami
    Boyle, Lee
    Hirman, Joe
    Asher, Divya
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
  • [14] Eptinezumab for Migraine Prevention in Patients 50 Years or Older: A Subgroup Analysis of PROMISE-1 and PROMISE-2
    Martin, V.
    Tassorelli, C.
    Ettrup, A.
    Hirman, J.
    Cady, R.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 105 - 106
  • [15] Eptinezumab for Migraine Prevention in Patients 50 Years or Older: A Subgroup Analysis of PROMISE-1 and PROMISE-2
    Martin, V.
    Tassorelli, C.
    Ettrup, A.
    Hirman, J.
    Cady, R.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 157 - 157
  • [16] Measuring dose-related efficacy of eptinezumab for migraine prevention: Post hoc analysis of PROMISE-1 and PROMISE-2
    Apelian, R. G.
    Boyle, L.
    Hirman, J.
    Asher, D.
    HEADACHE, 2022, 62 : 151 - 152
  • [17] Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2
    Rami Apelian
    Lee Boyle
    Joe Hirman
    Divya Asher
    The Journal of Headache and Pain, 2022, 23
  • [18] Eptinezumab for migraine prevention in patients 50 years or older: A subgroup analysis of PROMISE-1 and PROMISE-2
    Martin, V. T.
    Tassorelli, C.
    Ettrup, A.
    Hirman, J.
    Cady, R.
    HEADACHE, 2021, 61 : 125 - 126
  • [19] Efficacy and Safety of Eptinezumab in Patients With Chronic Migraine PROMISE-2 (vol 94, pg e1365, 2020)
    Lipton
    NEUROLOGY, 2023, 101 (06)
  • [20] Eptinezumab Reduced Migraine Activity and Achieved High Migraine Responder Rates over Weeks 1-12: Results from the Phase 3 PROMISE-2 Trial in Chronic Migraine
    Winner, P. K.
    Goadsby, P.
    Nagy, A.
    Brandes, J.
    Biondi, D.
    Bhattacharya, S.
    Cady, R.
    Hirman, J.
    Kassel, E.
    HEADACHE, 2018, 58 : 73 - 74
12345